Several clinical trials have been conducted to investigate isotypes of PD-L1 therapies, such as Pembrolizumab, which was approved by the FDA in May 2017 to treat MSI-H/dMMR advanced CRC patients that progressed on conventional chemotherapy. This evidence concerns the gene CD274 and colorectal carcinoma.